Pharma giant, GSK, plans to invest £200 million ($253 million) into the UK over the next two years and has acquired Aiolos Bio for $1.1 billion (£870 million).
The small molecule drug Ojjaara (momelotinib), developed by GlaxoSmithKline, has become the first U.S. Food and Drug Administration (FDA)-approved treatment for patients with the blood cancer myelofibrosis and anemia.
Leaders from some of the industry’s most notable companies are working together to streamline and automate IDMP workflow and come up with various standards.
The Oxford-GSK Institute of Molecular and Computational Medicine has been created via a five-year collaboration between GlaxoSmithKline and the University of Oxford.
Nucala, a monoclonal antibody indicated for patients with chronic rhinosinusitis with nasal polyps, has been approved by the Food and Drug Administration.
GSK announces it initiated Phase III trials for gepotidacin, the first in a new class of antibiotics, as an potential treatment for urinary tract infection.
A consortium between CPI and the University of Strathclyde aims to create a direct compression platform for continuous manufacturing of oral solid dosage drugs.
GSK taps Lyell’s technology to delay ‘exhaustion’ of T cells and will explore creating a new platform to develop cell and gene therapies for rare cancers.
US FDA approves AstraZeneca’s at-home autoinjector for administration of an add-on treatment for severe asthma, matching the indication of GSK’s rival product, Nucala.
Engineered cardiac tissues generated using Tara Biosystems' heart-on-a-chip system predict how patients will respond to a range of drugs, as demonstrated in a recent study with GSK.
GSK has announced a shakeup of its UK network, shelving plans for Ulverston biopharma plant, mooting the sale of its cephalosporin antibiotics business and pledging to invest in HIV and respiratory drug capacity.
GSK has warned that Donald Trump’s plan to encourage US drug production through import tax hikes must take the global nature of pharma supply chains into account.
GSK will pump £275m ($360m) into its UK manufacturing network and says the country has a “leading position in life sciences” despite the recent Brexit vote.
A GlaxoSmithKline plant in China that was hit by an explosion in the summer has had its Good Manufacturing Practice (GMP) certificate revoked by the UK medicines regulator.
GlaxoSmithKline was forced to briefly shutter its Zebulon, NC, manufacturing facility after the company discovered legionella bacteria in one of its cooling towers.
GSK is investing £38m ($60m) in enzymatic manufacturing at an antibiotic facility in Singapore which the firm says is greener and more efficient than traditional approaches.
Lupin will co-develop a rival to GSK’s Advair in the US and has licensed rights to an inhaled drug delivery tech competitor for Forest Labs’s Aerochamber.
Recipharm will acquire a facility and add technologies including spray granulation and spray coating as part of a “truly strategic” collaboration with France-based Flamel Technologies.
Codexis has felt the impact of Gilead’s Sovaldi with product revenues tumbling almost 60% due to the reduction in its hepatitis C biocatalyst and intermediate business.
Contract sales and marketing people who want to work for GSK should think about adopting the new target-free remuneration policy the UK pharmaceutical firm outlined earlier this week.
India’s top drug regulator on Wednesday unveiled a list of all the pending clinical trials before its apex committee, which includes information on what the top CROs are working on in the subcontinent.
A lack of understanding and commentary on proceedings may be putting some pharma firms off opting into the UK’s Patent Box scheme, according to a legal expert.
Amidst accusations of widespread bribery and corruption in China, GlaxoSmithKline has appointed Herve Gisserot as its new head of business in the country.
Drug industry groups welcomed corporate tax cuts and increased research credits set out in the UK budget last night suggesting they are good news for manufacturers.
Two major takeovers dominate the headlines this week with GSK finally securing its takeover of HGS and Par Pharmaceutical agreeing to be bought by private-equity firm TGS.
Pfizer will sell Mylan its dry-powder inhaler delivery system in an agreement set to pit the generics firm against UK drug major GlaxoSmithKline (GSK).
GlaxoSmithKline (GSK) is investing more than CA$30m (€21m) to add dermatology product manufacturing capabilities and create 70 jobs at a Canadian plant.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Gentium, Endo Pharmaceuticals and American Peptide Company.
GSK and Teva will invest in Russian drug manufacturing in response to PM Vladimir Putin’s warning that Pharmas will face restrictions if they fail to boost local production and transfer technology.
GlaxoSmithKline will sell its oral penicillin manufacturing facility in Tennessee, US, to Dr Reddy’s for an undisclosed sum, along with US rights to its Augmentin and Amoxin brands.
UK-drugmaker GlaxoSmithKline (GSK) must pay $750m to settle a law suit criticising manufacturing practices at plant in Cidra, Puerto Rico that was shut down in 2009.
Worrying times lie ahead for Pfizer’s advertiser, Aegis Group’s Carat, as the drug giant has decided to review its $1.3bn media account, as the firm is speculated to be slashing its outgoings.